Article
TFE3 activation in a TSC1-altered malignant PEComa: challenging the dichotomy of the underlying pathogenic mechanisms.
The journal of pathology. Clinical research - 1 Jan 2021
Schmiester Maren, Dolnik Anna, Kornak Uwe, Pfitzner Berit, Hummel Michael, Treue Denise, Hartmann Arndt, Agaimy Abbas, Weyerer Veronika, Lekaj Anja, Brakemeier Susanne, Peters Robert, Öllinger Robert, Märdian Sven, Bullinger Lars, Striefler Jana Käthe, Flörcken Anne
Abstract excerpt
Perivascular epithelioid cell tumors (PEComas) form a family of rare mesenchymal neoplasms that typically display myomelanocytic differentiation. Upregulation of mTOR signaling due the inactivation of TSC1/2 (Tuberous Sclerosis 1 and 2) is believed to be a key oncogenic driver in this disease. Recently, a subgroup of PEComas harboring TFE3 (Transcription Factor E3) rearrangements and presenting with a distinctive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
